[1]
|
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A. and Jemal, A. (2018) Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 68, 394-424. https://doi.org/10.3322/caac.21492
|
[2]
|
Di Corpo, M., Schlottmann, F., Strassle, P.D., Nurczyk, K. and Patti, M.G. (2019) Treatment Modalities for Esophageal Adenocarcinoma in the United States: Trends and Survival Outcomes. Journal of Laparoendoscopic & Advanced Surgical Techniques, 29, 989-994. https://doi.org/10.1089/lap.2019.0350
|
[3]
|
van den Ende, T., Smyth, E., Hulshof, M. and van Laarhoven, H.W.M. (2018) Chemotherapy and Novel Targeted Therapies for Operable Esophageal and Gastroesophageal Junctional Cancer. Best Practice & Research Clinical Gastroenterology, 36-37, 45-52. https://doi.org/10.1016/j.bpg.2018.11.005
|
[4]
|
Ku, G.Y. (2017) Systemic Therapy for Esophageal Cancer: Chemotherapy. Chinese Clinical Oncology, 6, Article No. 49. https://doi.org/10.21037/cco.2017.07.06
|
[5]
|
Maeda, O. and Ando, Y. (2019) Recent Progress of Chemotherapy and Biomarkers for Gastroesophageal Cancer. World Journal of Gastrointestinal Oncology, 11, 518-526. https://doi.org/10.4251/wjgo.v11.i7.518
|
[6]
|
Schizas, D., Charalampakis, N., Kole, C., Mylonas, K.S., Katsaros, I., Zhao, M., et al. (2020) Immunotherapy for Esophageal Cancer: A 2019 Update. Immunotherapy, 12, 203-218. https://doi.org/10.2217/imt-2019-0153
|
[7]
|
Kawazoe, A., Kuwata, T., Kuboki, Y., Shitara, K., Nagatsuma, A.K., Aizawa, M., et al. (2017) Clinicopathological Features of Programmed Death Ligand 1 Expression with Tumor-Infiltrating Lymphocyte, Mismatch Repair, and Epstein-Barr Virus Status in a Large Cohort of Gastric Cancer Patients. Gastric Cancer, 20, 407-415.
https://doi.org/10.1007/s10120-016-0631-3
|
[8]
|
Zhu, Y., Li, M., Bo, C., Liu, X., Zhang, J., Li, Z., et al. (2017) Prognostic Significance of the Lymphocyte-to-Monocyte Ratio and the Tumor-Infiltrating Lymphocyte to Tumor-Associated Macrophage Ratio in Patients with Stage T3N0M0 Esophageal Squamous Cell Carcinoma. Cancer Immunology, Immunotherapy, 66, 343-354.
https://doi.org/10.1007/s00262-016-1931-5
|
[9]
|
Svensson, M.C., Warfvinge, C.F., Fristedt, R., Hedner, C., Borg, D., Eberhard, J., et al. (2017) The Integrative Clinical Impact of Tumor-Infiltrating T Lymphocytes and NK Cells in Relation to B Lymphocyte and Plasma Cell Density in Esophageal and Gastric Adenocarcinoma. Oncotarget, 8, 72108-72126. https://doi.org/10.18632/oncotarget.19437
|
[10]
|
Chen, K. and Sun, B. (2020) Incidence and Risk of PD-1/PD-L1 Inhibitor-Associated Pneumonia in Advance Cancer Patients: A Meta-Analysis. Chinese Journal of Lung Cancer, 23, 927-940.
|
[11]
|
Borghaei, H., Gettinger, S., Vokes, E.E., Chow, L.Q.M., Burgio, M.A., et al. (2021) Five-Year Outcomes from the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 39, 723-733. https://doi.org/10.1200/JCO.20.01605
|
[12]
|
Attia, H. and Smyth, E. (2021) Evolving Therapies in Advanced Oesophago-Gastric Cancers and the Increasing Role of Immunotherapy. Expert Review of Anticancer Therapy, 21, 535-546.
https://doi.org/10.1080/14737140.2021.1866548
|
[13]
|
Olivo, S.A., Macedo, L.G., Gadotti, I.C., Fuentes, J., Stanton, T. and Magee, D.J. (2008) Scales to Assess the Quality of Randomized Controlled Trials: A Systematic Review. Physical Therapy 88, 156-175.
https://doi.org/10.2522/ptj.20070147
|
[14]
|
Muro, K., Kojima, T., Moriwaki, T., et al. (2021) Second-Line Pembrolizumab versus Chemotherapy in Japanese Patients with Advanced Esophageal Cancer: Subgroup Analysis from KEYNOTE-181. Esophagus, 1-9.
|
[15]
|
Shitara, K., Ozguroglu, M., Bang, Y.J., Di Bartolomeo, M., Mandalà, M., Ryu, M.H., et al. (2018) Pembrolizumab versus Paclitaxel for Previously Treated, Advanced Gastric or Gastro-Oesophageal Junction Cancer (KEYNOTE-061): A Randomised, Open-Label, Controlled, Phase 3 Trial. Lancet, 392, 123-133.
https://doi.org/10.1016/S0140-6736(18)31257-1
|
[16]
|
Takahashi, M., Kato, K., Okada, M., et al. (2021) Nivolumab versus Chemotherapy in Japanese Patients with Advanced Esophageal Squamous Cell Carcinoma: A Subgroup Analysis of a Multicenter, Randomized, Open-Label, Phase 3 Trial (ATTRACTION-3). Esophagus, 18, 90-99. https://doi.org/10.1007/s10388-020-00794-x
|
[17]
|
Bang, Y.J., Ruiz, E.Y., Van Cutsem, E., Lee, K.W., Wyrwicz, L., Schenker, M., et al. (2018) Phase III, Randomised trial of Avelumab versus Physician’s Choice of Chemotherapy as Third-Line Treatment of Patients with Advanced Gastric or Gastro-Oesophageal Junction Cancer: Primary Analysis of JAVELIN Gastric 300. Annals of Oncology, 29, 2052-2060. https://doi.org/10.1093/annonc/mdy264
|
[18]
|
Kang, Y.K., Boku, N., Satoh, T., Ryu, M.H., Chao, Y., Kato, K, et al. (2017) Nivolumab in Patients with Advanced Gastric or Gastro-Oesophageal Junction Cancer Refractory to, or Intolerant of, at Least Two Previous Chemotherapy Regimens (ONO-4538-12, ATTRACTION-2): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial. Lancet, 390, 2461-2471. https://doi.org/10.1016/S0140-6736(17)31827-5
|
[19]
|
傅剑华, 谭子辉. 食管癌外科治疗的现状与未来展望[J]. 中国肿瘤临床, 2016, 43(12): 507-510.
|
[20]
|
Eyck, B.M., van Lanschot, J.J.B., Hulshof, M.C., et al. (2021) Ten-Year Outcome of Neoadjuvant Chemoradiotherapy plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 39, 1995-2004.
|
[21]
|
Darvin, P., Toor, S.M., Sasidharan, N.V. and Elkord, E. (2018) Immune Checkpoint Inhibitors: Recent Progress and Potential Biomarkers. Experimental & Molecular Medicine, 50, 1-11. https://doi.org/10.1038/s12276-018-0191-1
|
[22]
|
Freeman, G.J., Long, A.J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., et al. (2000) Engagement of the PD-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation. Journal of Experimental Medicine, 192, 1027-1034. https://doi.org/10.1084/jem.192.7.1027
|
[23]
|
Patsoukis, N., Wang, Q., Strauss, L. and Boussiotis, V.A. (2020) Revisiting the PD-1 Pathway. Science Advances, 6, Article No. eabd2712. https://doi.org/10.1126/sciadv.abd2712
|
[24]
|
Reynolds, J., Sando, G.S., Marsh, O.B., Salama, A.D., Evans, D.J., Cook, H.T., et al. (2012) Stimulation of the PD-1/PDL-1 T-Cell Co-Inhibitory Pathway Is Effective in Treatment of Experimental Autoimmune Glomerulonephritis. Nephrology Dialysis Transplantation, 27, 1343-1350. https://doi.org/10.1093/ndt/gfr529
|
[25]
|
Zhou, K., Guo, S., Li, F., Sun, Q. and Liang, G. (2020) Exosomal PD-L1: New Insights into Tumor Immune Escape Mechanisms and Therapeutic Strategies. Frontiers in Cell and Developmental Biology, 8, Article ID: 569219.
https://doi.org/10.3389/fcell.2020.569219
|
[26]
|
Jiang, X., Wang, J., Deng, X., Xiong, F., Ge, J., Xiang, B., et al. (2019) Role of the Tumor Microenvironment in PD-L1/PD-1-Mediated Tumor Immune Escape. Molecular Cancer, 18, Article No. 10.
https://doi.org/10.1186/s12943-018-0928-4
|
[27]
|
Barsouk, A., Rawla, P., Hadjinicolaou, A.V., Aluru, J.S. and Barsouk, A. (2019) Targeted Therapies and Immunotherapies in the Treatment of Esophageal Cancers. Medical Sciences, 7, Article No. 100.
https://doi.org/10.3390/medsci7100100
|
[28]
|
Gong, J., Chehrazi-Raffle, A., Reddi, S. and Salgia, R. (2018) Development of PD-1 and PD-L1 Inhibitors as a Form of Cancer Immunotherapy: A Comprehensive Review of Registration Trials and Future Considerations. Journal for ImmunoTherapy of Cancer, 6, Article No. 8. https://doi.org/10.1186/s40425-018-0316-z
|
[29]
|
Huang, J., Xu, J., Chen, Y., et al. (2020) Camrelizumab versus Investigator's Choice of Chemotherapy as Second-Line Therapy for Advanced or Metastatic Oesophageal Squamous Cell Carcinoma (ESCORT): A Multicentre, Randomised, Open-Label, Phase 3 Study. The Lancet Oncology, 21, 832-842. https://doi.org/10.1016/S1470-2045(20)30110-8
|
[30]
|
Xu, J., Li, Y., Fan, Q., et al. (2020) Sintilimab in Patients with Advanced Esophageal Squamous Cell Carcinoma Refractory to Previous Chemotherapy: A Randomized, Open-Label Phase II Trial (ORIENT-2). American Society of Clinical Oncology. https://doi.org/10.1200/JCO.2020.38.15_suppl.4511
|
[31]
|
Sanmartin, O., Beato, C., Suh-Oh, H.J., Aragón, I., España, A., Majem, M., et al. (2019) Clinical Management of Cutaneous Adverse Events in Patients on Chemotherapy: A National Consensus Statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology. Actas Dermo-Sifiliográficas (English Edition), 110, 448-459. https://doi.org/10.1016/j.adengl.2019.05.003
|
[32]
|
Voutsadakis, I.A. (2018) Clinical Tools for Chemotherapy Toxicity Prediction and Survival in Geriatric Cancer Patients. Journal of Chemotherapy, 30, 266-279. https://doi.org/10.1080/1120009X.2018.1475442
|